NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Price Target & More

$13.34 -0.10 (-0.74 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$13.34
Today's Range$13.26 - $13.6890
52-Week Range$7.55 - $14.99
Volume28,882 shs
Average Volume116,762 shs
Market Capitalization$248.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.32

About Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals logoFennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530

Debt

Debt-to-Equity RatioN/A
Current Ratio17.32%
Quick Ratio17.32%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.68 per share
Price / Book7.94

Profitability

EPS (Most Recent Fiscal Year)($0.47)
Net Income$-7,040,000.00
Net MarginsN/A
Return on Equity-58.56%
Return on Assets-54.40%

Miscellaneous

Employees3
Outstanding Shares18,470,000

How to Become a New Pot Stock Millionaire

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its earnings results on Monday, March, 26th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. View Fennec Pharmaceuticals' Earnings History.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, May, 11th 2018. View Earnings Estimates for Fennec Pharmaceuticals.

What price target have analysts set for FENC?

3 Wall Street analysts have issued 1-year price objectives for Fennec Pharmaceuticals' stock. Their predictions range from $17.00 to $22.00. On average, they anticipate Fennec Pharmaceuticals' share price to reach $19.00 in the next year. View Analyst Ratings for Fennec Pharmaceuticals.

Who are some of Fennec Pharmaceuticals' key competitors?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the folowing people:
  • Khalid Islam Ph.D., Chairman of the Board (Age 61)
  • Rostislav C. Raykov, Chief Executive Officer, Director (Age 39)
  • Robert C. Andrade, Chief Financial Officer (Age 39)
  • Marco Maria Brughera, Director (Age 60)
  • Adrian J. Haigh, Independent Director (Age 56)
  • Chris A. Rallis, Independent Director (Age 61)
  • Steven D. Skolsky, Independent Director (Age 61)

Has Fennec Pharmaceuticals been receiving favorable news coverage?

News coverage about FENC stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also gave news stories about the company an impact score of 46.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $13.34.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $248.17 million. The company earns $-7,040,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Fennec Pharmaceuticals employs 3 workers across the globe.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.


MarketBeat Community Rating for Fennec Pharmaceuticals (FENC)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fennec Pharmaceuticals (NASDAQ:FENC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Fennec Pharmaceuticals in the last 12 months. Their average twelve-month price target is $19.00, suggesting that the stock has a possible upside of 42.43%. The high price target for FENC is $22.00 and the low price target for FENC is $17.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.00$18.3333$22.00N/A
Price Target Upside: 42.43% upside74.60% upside126.80% upsideN/A

Fennec Pharmaceuticals (NASDAQ:FENC) Consensus Price Target History

Price Target History for Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals (NASDAQ:FENC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018HC WainwrightReiterated RatingBuy$18.00LowView Rating Details
3/12/2018WedbushInitiated CoverageOutperform$17.00HighView Rating Details
11/29/2017LaidlawInitiated CoverageBuy -> Buy$22.00HighView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Fennec Pharmaceuticals (NASDAQ:FENC) Earnings History and Estimates Chart

Earnings by Quarter for Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals (NASDAQ:FENC) Earnings Estimates

2018 EPS Consensus Estimate: ($0.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.17)($0.17)($0.17)

Fennec Pharmaceuticals (NASDAQ FENC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2018        
3/26/2018Q4 2017($0.14)($0.15)ViewN/AView Earnings Details
11/13/2017Q3 17($0.15)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.11)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.06)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.08)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.04)ViewN/AView Earnings Details
8/12/2016Q2 2016($0.06)ViewN/AView Earnings Details
5/12/2016Q1 2016($0.04)ViewN/AView Earnings Details
3/28/2016Q4 2015($0.05)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.01)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.02)ViewN/AView Earnings Details
5/15/2015Q1 2015($0.04)ViewN/AView Earnings Details
4/1/2015Q4 2014$0.14ViewN/AView Earnings Details
11/13/2014Q3 2014$0.03ViewN/AView Earnings Details
8/11/2014Q2 2014($0.09)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.06)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.03)ViewN/AView Earnings Details
11/15/2013Q3 2013($0.21)ViewN/AView Earnings Details
8/9/2013Q2 2013$0.78ViewN/AView Earnings Details
5/13/2013Q1 2013($0.06)ViewN/AView Earnings Details
4/1/2013Q4 2012($0.12)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.09)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.06)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.52)ViewN/AView Earnings Details
5/13/2011Q1 2011$0.54ViewN/AView Earnings Details
3/31/2011Q4 2010($1.08)ViewN/AView Earnings Details
11/15/2010Q3 2010$0.54ViewN/AView Earnings Details
11/12/2008Q3 2008($1.62)ViewN/AView Earnings Details
8/13/2008Q2 2008($1.62)ViewN/AView Earnings Details
5/13/2008Q1 2008($1.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Fennec Pharmaceuticals (NASDAQ:FENC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Fennec Pharmaceuticals (NASDAQ FENC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.70%
Institutional Ownership Percentage: 38.80%
Insider Trading History for Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals (NASDAQ FENC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2018Manchester Management Pr, LlcMajor ShareholderSell914,745$10.61$9,705,444.45View SEC Filing  
12/12/2017Spa EssetifinMajor ShareholderBuy294,115$8.50$2,499,977.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fennec Pharmaceuticals (NASDAQ FENC) News Headlines

Source:
DateHeadline
 Brokerages Set $17.50 Price Target for Fennec Pharmaceuticals Inc (FENC) Brokerages Set $17.50 Price Target for Fennec Pharmaceuticals Inc (FENC)
www.americanbankingnews.com - April 16 at 9:25 AM
Zacks: Brokerages Expect Fennec Pharmaceuticals Inc (FENC) Will Announce Earnings of -$0.14 Per ShareZacks: Brokerages Expect Fennec Pharmaceuticals Inc (FENC) Will Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 12 at 1:25 PM
Fennec Pharmaceuticals (FENC) Upgraded by ValuEngine to "Hold"Fennec Pharmaceuticals (FENC) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 3 at 3:37 PM
Fennec Pharmaceuticals (FENC) Given Buy Rating at HC WainwrightFennec Pharmaceuticals (FENC) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 2 at 8:03 AM
Zacks: Fennec Pharmaceuticals Inc (FENC) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: Fennec Pharmaceuticals Inc (FENC) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 30 at 7:42 AM
Equities Analysts Issue Forecasts for Fennec Pharmaceuticals Incs Q1 2018 Earnings (FENC)Equities Analysts Issue Forecasts for Fennec Pharmaceuticals Inc's Q1 2018 Earnings (FENC)
www.americanbankingnews.com - March 30 at 6:46 AM
Fennec Pharmaceuticals Inc (FENC) Major Shareholder Sells $9,705,444.45 in StockFennec Pharmaceuticals Inc (FENC) Major Shareholder Sells $9,705,444.45 in Stock
www.americanbankingnews.com - March 29 at 10:10 PM
Fennec Pharmaceuticals (FENC) Granted Breakthrough Therapy Designation by FDA for PEDMARKFennec Pharmaceuticals (FENC) Granted Breakthrough Therapy Designation by FDA for PEDMARK
www.streetinsider.com - March 29 at 4:17 PM
FY2020 EPS Estimates for Fennec Pharmaceuticals Inc Reduced by Wedbush (FENC)FY2020 EPS Estimates for Fennec Pharmaceuticals Inc Reduced by Wedbush (FENC)
www.americanbankingnews.com - March 29 at 8:46 AM
Fennec Flat After FDA Nod for PEDMARKFennec Flat After FDA Nod for PEDMARK
www.baystreet.ca - March 27 at 4:14 PM
Fennec Pharmaceuticals Inc. (FENC) PT Maintained at $17 at Wedbush on PEDMARK Update; Approval Outlook ImprovesFennec Pharmaceuticals Inc. (FENC) PT Maintained at $17 at Wedbush on PEDMARK Update; 'Approval Outlook Improves'
www.streetinsider.com - March 27 at 4:14 PM
Fennec Pharmaceuticals receives Breakthrough Therapy designation by FDA for PEDMARKFennec Pharmaceuticals receives Breakthrough Therapy designation by FDA for PEDMARK
seekingalpha.com - March 27 at 10:08 AM
Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™
finance.yahoo.com - March 27 at 10:08 AM
Fennecs stock soars further after PEDMARK receives breakthrough therapy designationFennec's stock soars further after PEDMARK receives 'breakthrough therapy' designation
finance.yahoo.com - March 27 at 10:08 AM
Fennec receives new FDA designation as company readies for commercial launchFennec receives new FDA designation as company readies for commercial launch
finance.yahoo.com - March 27 at 10:08 AM
Fennec Pharmaceuticals Inc (FENC) Expected to Announce Earnings of -$0.14 Per ShareFennec Pharmaceuticals Inc (FENC) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - March 26 at 3:26 PM
Fennec Provides Business Update and Announces...Fennec Provides Business Update and Announces...
www.benzinga.com - March 26 at 10:09 AM
Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial ResultsFennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
finance.yahoo.com - March 26 at 10:09 AM
Fennec Pharmaceuticals (FENC) Rating Increased to Hold at ValuEngineFennec Pharmaceuticals (FENC) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM
3 Things In Biotech, March 22: Sun Is In, Fennec Moving Fast, Fortress Heads Out3 Things In Biotech, March 22: Sun Is In, Fennec Moving Fast, Fortress Heads Out
seekingalpha.com - March 24 at 4:11 PM
Fennec Pharmaceuticals (FENC) Stock Rating Reaffirmed by HC WainwrightFennec Pharmaceuticals (FENC) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 22 at 2:27 PM
Good news for Fennec ahead of FDA submissionGood news for Fennec ahead of FDA submission
finance.yahoo.com - March 21 at 4:12 PM
Fennec Pharmaceuticals (FENC) and AzurRx BioPharma (AZRX) Financial ComparisonFennec Pharmaceuticals (FENC) and AzurRx BioPharma (AZRX) Financial Comparison
www.americanbankingnews.com - March 18 at 9:12 PM
Brokers Issue Forecasts for Fennec Pharmaceuticals Incs FY2017 Earnings (FENC)Brokers Issue Forecasts for Fennec Pharmaceuticals Inc's FY2017 Earnings (FENC)
www.americanbankingnews.com - March 15 at 7:25 AM
Zacks: Fennec Pharmaceuticals Inc (FENC) Given $16.50 Consensus Target Price by AnalystsZacks: Fennec Pharmaceuticals Inc (FENC) Given $16.50 Consensus Target Price by Analysts
www.americanbankingnews.com - March 15 at 5:23 AM
Fennec Pharmaceuticals (FENC) Receives New Coverage from Analysts at WedbushFennec Pharmaceuticals (FENC) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - March 12 at 9:22 PM
Zacks: Analysts Expect Fennec Pharmaceuticals Inc (FENC) to Announce -$0.15 Earnings Per ShareZacks: Analysts Expect Fennec Pharmaceuticals Inc (FENC) to Announce -$0.15 Earnings Per Share
www.americanbankingnews.com - March 9 at 12:42 PM
Analysts Anticipate Fennec Pharmaceuticals Inc (FENC) to Post ($0.15) Earnings Per ShareAnalysts Anticipate Fennec Pharmaceuticals Inc (FENC) to Post ($0.15) Earnings Per Share
www.americanbankingnews.com - March 9 at 1:12 AM
Critical Analysis: Fennec Pharmaceuticals (FENC) versus Its CompetitorsCritical Analysis: Fennec Pharmaceuticals (FENC) versus Its Competitors
www.americanbankingnews.com - February 23 at 11:12 PM
 Fennec Pharmaceuticals Inc (FENC) Given $16.00 Consensus Price Target by Analysts Fennec Pharmaceuticals Inc (FENC) Given $16.00 Consensus Price Target by Analysts
www.americanbankingnews.com - February 22 at 11:44 AM
Fennec Pharmaceuticals (FENC) Receives New Coverage from Analysts at HC WainwrightFennec Pharmaceuticals (FENC) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - February 20 at 11:30 AM
ValuEngine Lowers Fennec Pharmaceuticals (FENC) to SellValuEngine Lowers Fennec Pharmaceuticals (FENC) to Sell
www.americanbankingnews.com - December 24 at 6:26 PM
Fennec Pharmaceuticals Inc (FENC) Major Shareholder Spa Essetifin Acquires 294,115 SharesFennec Pharmaceuticals Inc (FENC) Major Shareholder Spa Essetifin Acquires 294,115 Shares
www.americanbankingnews.com - December 14 at 5:34 PM
Fennec’s $20M offering primes company for 2019 commercial launchFennec’s $20M offering primes company for 2019 commercial launch
finance.yahoo.com - December 11 at 9:28 AM
Fennec Pharmaceuticals (FENC) Prices 2.35M Common Stock Offering at $8.50/ShareFennec Pharmaceuticals (FENC) Prices 2.35M Common Stock Offering at $8.50/Share
www.streetinsider.com - December 10 at 8:50 AM
Adherex Technologies (FENC) Now Covered by Analysts at LaidlawAdherex Technologies (FENC) Now Covered by Analysts at Laidlaw
www.americanbankingnews.com - November 29 at 1:00 PM
Mitsubishi Connect Provides Enriched, More Personalized Driving ExperienceMitsubishi Connect Provides Enriched, More Personalized Driving Experience
www.businesswire.com - November 28 at 5:55 PM
Adherex Technologies Inc. (FENC) Announces  Earnings ResultsAdherex Technologies Inc. (FENC) Announces Earnings Results
www.americanbankingnews.com - November 14 at 9:56 AM
Cirrus Logic (CRUS) Q2 2018 Results - Earnings Call TranscriptCirrus Logic (CRUS) Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - November 3 at 12:24 PM
Symantec (SYMC) Q2 2018 Results - Earnings Call TranscriptSymantec (SYMC) Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 12:46 AM
The 5 Best Growth Stocks in Tech for 2018The 5 Best Growth Stocks in Tech for 2018
www.nasdaq.com - October 20 at 12:24 AM
Fennec banks positive results on heels of move to NasdaqFennec banks positive results on heels of move to Nasdaq
finance.yahoo.com - October 19 at 7:23 PM
Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 MeetingFennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
finance.yahoo.com - October 16 at 7:03 PM
Fennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York CityFennec to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017 in New York City
finance.yahoo.com - September 20 at 7:37 PM
Safety Dynamics, Beeper Communications and Mantaro Networks Sign Strategic Technology Alliance to Support Public Safety and Gunshot DetectionSafety Dynamics, Beeper Communications and Mantaro Networks Sign Strategic Technology Alliance to Support Public Safety and Gunshot Detection
www.bizjournals.com - September 20 at 2:44 AM
IIROC Trade Resumption - Fennec Pharmaceuticals Inc.IIROC Trade Resumption - Fennec Pharmaceuticals Inc.
finance.yahoo.com - September 19 at 4:41 PM

SEC Filings

Fennec Pharmaceuticals (NASDAQ:FENC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fennec Pharmaceuticals (NASDAQ:FENC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fennec Pharmaceuticals (NASDAQ FENC) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.